Biography
Maarten IJzerman (Dutch, Australian) is Dean of Erasmus School of Health Policy & Management and Professor of Cancer Health Services Research in Erasmus University. He also is (honorary) Professor in the Melbourne School of Population and Global Health and University of Melbourne Centre for Cancer Research.
Maarten studied biomedical sciences (Radboud University Nijmegen, Faculty of Medical Sciences) and received his PhD in biomedical engineering (University of Twente, Faculty of Electrical Engineering).
In his research he takes a systems approach to health (technology) innovation and cancer management. He leads work in genomics enable precision oncology including improving cancer outcomes across the whole episode of care. Current initiatives aim to promote access to cancer care across the globe, with an emphasis on global health challenges and healthcare sustainability.
Maarten is an INSEAD alumnus (International Directors Program, Singapore) and received certificates from University of York (Health Economics) and Colombia University (Corporate Finance) and serves as a non-executive board member in the non-profit sector.
Erasmus School of Health Policy & Management
Dean | Erasmus School of Health Policy & Management
- ijzerman@eshpm.eur.nl
Erasmus School of Health Policy & Management
Full professor | Health Services Management & Organisation (HSMO)
- ijzerman@eshpm.eur.nl
More information
Work
- Praveen Thokala, Nancy Devlin, Kevin Marsh, Rob Baltussen, Meindert Boysen, Zoltan Kalo, Thomas Longrenn, Filip Mussen, Stuart Peacock, John Watkins & Maarten Ijzerman (2016) - Multiple criteria decision analysis for health care decision making - An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force - Value in Health, 19 (1), 125-137 - doi: 10.1016/j.jval.2015.12.003 - [link]
- A. Brett Hauber, Juan Marcos González, Catharina G.M. Groothuis-Oudshoorn, Thomas Prior, Deborah A. Marshall, Charles Cunningham, Maarten J. IJzerman & John F.P. Bridges (2016) - Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force - Value in Health, 19 (4), 300-315 - doi: 10.1016/j.jval.2016.04.004 - [link]
- William V Padula, Noemi Kreif, David J Vanness, Blythe Adamson, Juan-David Rueda, Federico Felizzi, Pall Jonsson, Maarten J IJzerman, Atul Butte & William Crown (2022) - Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force - Value in Health, 25 (7), 1063-1080 - doi: 10.1016/j.jval.2022.03.022 - [link]
- Maarten J. Ijzerman & Lotte M.G. Steuten (2011) - Early assessment of medical technologies to inform product development and market access: A review of methods and applications - Applied Health Economics and Health Policy, 9 (5), 331-347 - doi: 10.2165/11593380-000000000-00000 - [link]
- Koen Degeling, Nancy N. Baxter, Jon Emery, Mark A. Jenkins, Fanny Franchini, Peter Gibbs, G. Bruce Mann, Grant McArthur, Benjamin J. Solomon & Maarten J. IJzerman (2021) - An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic - Asia-Pacific Journal of Clinical Oncology, 17 (4), 359-367 - doi: 10.1111/ajco.13505 - [link]
- Sophie O’Haire, Koen Degeling, Fanny Franchini, Ben Tran, Stephen J. Luen, Clara Gaff, Kortnye Smith, Stephen Fox, Jayesh Desai & Maarten IJzerman (2022) - Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm - Targeted Oncology, 17 (5), 539-548 - doi: 10.1007/s11523-022-00910-0 - [link]
- Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman & Maarten J. IJzerman (2022) - Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review - European Journal of Haematology, 108 (6), 469-485 - doi: 10.1111/ejh.13755 - [link]
- Mussab Fagery, Hadi A Khorshidi, Stephen Q Wong, Martin Vu & Maarten IJzerman (2023) - Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review - PharmacoEconomics, 41 (10), 1229-1248 - doi: 10.1007/s40273-023-01292-5 - [link]
- Koen Degeling, Maarten J. IJzerman, Catharina G.M. Groothuis-Oudshoorn, Mira D. Franken, Miriam Koopman, Mark S. Clements & Hendrik Koffijberg (2022) - Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer - Value in Health, 25 (1), 104-115 - doi: 10.1016/j.jval.2021.07.016 - [link]
- Sophie O’Haire, Fanny Franchini, Yoon Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox & Maarten IJzerman (2023) - Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours - Scientific Reports, 13 (1) - doi: 10.1038/s41598-023-31055-3 - [link]
- Maarten IJzerman (20 september 2024) - Opinie: Mislukte concentratie kinderhartchirurgie leidt tot toekomstlessen
- Maarten IJzerman & Stefan Sleijfer (6 juni 2024) - Neem duurzaamheid en personeelstekorten mee in het pakketbeheer
- Maarten IJzerman (10 mei 2022) - Will Australia be left behind in the cancer genomics revolution?
- Maarten IJzerman & Sarah-Jane Dawson (15 februari 2021) - Testing, testing, testing: Can blood tests help detect cancers early?
- Maarten IJzerman (29 september 2020) - Nieuwe kankermedicijnen: eerst veiligheid, dan snel naar patiënten
- Maarten IJzerman (12 juni 2020) - Costly, fatal delays, new model shows
- Maarten IJzerman (1 mei 2020) - How has the temporary closure of BreastScreen affected GPs?
- Maarten IJzerman & Jon D. Emery (30 april 2020) - Is a delayed cancer diagnosis a consequence of COVID-19?
- Maarten IJzerman (18 mei 2019) - Improving Australia’s health system beyond the election
- Maarten IJzerman & Kim Dalziel (16 mei 2019) - Improving Australia’s health system beyond the election
Laboratorium Microbiologie
- Start date approval
- januari 2023
- End date approval
- november 2025
- Place
- HENGELO
- Description
- Lid Raad van Toezicht
Erasmus Centrum voor Zorgbestuur b.v.
- Start date approval
- juli 2023
- End date approval
- juni 2026
- Place
- ROTTERDAM
- Description
- Lid Raad van Commissarisen ECZB b.v. namens de EUR
Erasmus Trust Fund
- Start date approval
- september 2023
- End date approval
- augustus 2026
- Place
- ROTTERDAM
- Description
- Lid Bestuur Erasmus Trust Fund
University of Melbourne
- Start date approval
- november 2023
- End date approval
- november 2026
- Place
- MELBOURNE
- Description
- Visiting professor honorary
International Society for Pharmacoeconomics ISPOR
- Start date approval
- februari 2024
- End date approval
- februari 2027
- Place
- PHILADELPHIA
- Description
- Chair Health Sciences Policy Council
Erasmus Enterprise b.v.
- Start date approval
- mei 2024
- End date approval
- mei 2026
- Place
- ROTTERDAM
- Description
- Commissaris
Medical innovation
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- BM02MBI
